197 related articles for article (PubMed ID: 23588203)
41. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
[TBL] [Abstract][Full Text] [Related]
42. PRC2 regulates RNA polymerase III transcribed non-translated RNA gene transcription through EZH2 and SUZ12 interaction with TFIIIC complex.
Liu C; Li S; Dai X; Ma J; Wan J; Jiang H; Wang P; Liu Z; Zhang H
Nucleic Acids Res; 2015 Jul; 43(13):6270-84. PubMed ID: 26038315
[TBL] [Abstract][Full Text] [Related]
43. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
44. Polycomb-like 2 regulates PRC2 components to affect proliferation in glioma cells.
Wang F; Gao Y; Lv Y; Wu Y; Guo Y; Du F; Wang S; Yu J; Cao X; Li PA
J Neurooncol; 2020 Jun; 148(2):259-271. PubMed ID: 32436117
[TBL] [Abstract][Full Text] [Related]
45. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
46. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract][Full Text] [Related]
47. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
[TBL] [Abstract][Full Text] [Related]
48. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
[TBL] [Abstract][Full Text] [Related]
49. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
50. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Smith HW; Hirukawa A; Sanguin-Gendreau V; Nandi I; Dufour CR; Zuo D; Tandoc K; Leibovitch M; Singh S; Rennhack JP; Swiatnicki M; Lavoie C; Papavasiliou V; Temps C; Carragher NO; Unciti-Broceta A; Savage P; Basik M; van Hoef V; Larsson O; Cooper CL; Vargas Calderon AC; Beith J; Millar E; Selinger C; Giguère V; Park M; Harris LN; Varadan V; Andrechek ER; O'Toole SA; Topisirovic I; Muller WJ
Nat Commun; 2019 Jul; 10(1):2901. PubMed ID: 31263101
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia.
Ridinger-Saison M; Evanno E; Gallais I; Rimmelé P; Selimoglu-Buet D; Sapharikas E; Moreau-Gachelin F; Guillouf C
Cell Death Differ; 2013 Sep; 20(9):1268-78. PubMed ID: 23852375
[TBL] [Abstract][Full Text] [Related]
52. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
53. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
54. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
55. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
56. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
57. The polycomb group protein Suz12 is required for embryonic stem cell differentiation.
Pasini D; Bracken AP; Hansen JB; Capillo M; Helin K
Mol Cell Biol; 2007 May; 27(10):3769-79. PubMed ID: 17339329
[TBL] [Abstract][Full Text] [Related]
58. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Deb G; Thakur VS; Gupta S
Epigenetics; 2013 May; 8(5):464-76. PubMed ID: 23644490
[TBL] [Abstract][Full Text] [Related]
59. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.
Roy S; Yu Y; Padhye SB; Sarkar FH; Majumdar AP
PLoS One; 2013; 8(7):e68543. PubMed ID: 23894315
[TBL] [Abstract][Full Text] [Related]
60. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
